|
Study | N | Patients | Treatment | Outcome |
|
Wade et al. 2009 [40] | 5 | Renal transplant with mixed AMR and ACR | Bortezomib 1.3 mg/m2/dose × 4 | (i) Prompt AMR and ACR reversal (ii) Significant decrease in DSA levels |
|
Tanriover et al. 2008 [38] | 6 | Kidney/kidney pancreas transplant with mixed AMR and ACR | Same as above | (i) Prompt rejection reversal marked and prolonged reductions in DSA levels (ii) >50% decrease in DSA levels within 14 days and suppression for up to 5 months |
|
Celik et al. 2009 [37] | 2 | Positive crossmatch renal transplant recipient with AMR | Bortezomib 1.3 mg/m2/dose on days 1, 4, 8, 11 Daily plasmapheresis and IVIG | (i) Decrease HLA allospecificities (ii) Decrease in number of plasma cells in bone marrow |
|
Faguer et al. 2010 [39] | 4 | Renal transplant recipients with AMR and persistently elevated DSA | Bortezomib 1.3 mg/m2/dose × 4 | No significant decrease in DSA within 150 days post treatment |
|
Wade et al. 2009 [40] | 11 | Living donor renal transplant patients with anti-HLA alloantibodies | Bortezomib 1.3 mg/m2/dose with methylprednisolone 250 mg on days 1, 4, 8, 11 2–4 sessions of plasmapheresis 1 dose of rituximab (6 patients) | (i) Reduced DSA and non-DSA levels (ii) Stable graft function 4 months post treatment |
|
Faguer et al. 2010 [40] | 2 | Living donor renal transplant | Bortezomib 1.3 mg/m2/dose × 4 Ongoing plasmapheresis, rituximab, intravenous steroids | (i) Immediate significant reduction in DSA (ii) Stable graft function at 6 months post treatment |
|